[go: up one dir, main page]

MA33221B1 - Fusions de médicament et conjugués afférents - Google Patents

Fusions de médicament et conjugués afférents

Info

Publication number
MA33221B1
MA33221B1 MA34282A MA34282A MA33221B1 MA 33221 B1 MA33221 B1 MA 33221B1 MA 34282 A MA34282 A MA 34282A MA 34282 A MA34282 A MA 34282A MA 33221 B1 MA33221 B1 MA 33221B1
Authority
MA
Morocco
Prior art keywords
medicines
facilities
integration
fusions
conjugates
Prior art date
Application number
MA34282A
Other languages
Arabic (ar)
English (en)
Inventor
Christopher Herring
Lucy J Holt
Laurent S Jespers
Sebastian Mayer
Malgorzata Pupecka-Swider
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33221(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33221B1 publication Critical patent/MA33221B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des fusions de médicament qui possèdent des demi-vies sériques améliorées. Lesdites fusions et lesdits conjugués comprennent des polypeptides, des domaines variables uniques d'immunoglobuline (anticorps) et des molécules d'exendine et/ou de GLP. L'invention concerne en outre des utilisations, des formulations, des compositions et des dispositifs comprenant de telles fusions de médicaments et de tels conjugués.
MA34282A 2009-03-27 2010-03-24 Fusions de médicament et conjugués afférents MA33221B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27
PCT/EP2010/053806 WO2010108937A2 (fr) 2009-03-27 2010-03-24 Fusions de médicament et conjugués afférents

Publications (1)

Publication Number Publication Date
MA33221B1 true MA33221B1 (fr) 2012-04-02

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34282A MA33221B1 (fr) 2009-03-27 2010-03-24 Fusions de médicament et conjugués afférents

Country Status (24)

Country Link
US (2) US8779103B2 (fr)
EP (1) EP2411054A2 (fr)
JP (1) JP2012521971A (fr)
KR (1) KR20110137819A (fr)
CN (2) CN102481373A (fr)
AR (1) AR076147A1 (fr)
AU (1) AU2010227552B2 (fr)
BR (1) BRPI1013588A2 (fr)
CA (1) CA2756853A1 (fr)
CL (1) CL2011002387A1 (fr)
CO (1) CO6361953A2 (fr)
DO (1) DOP2011000288A (fr)
EA (1) EA021146B1 (fr)
IL (1) IL215200A0 (fr)
MA (1) MA33221B1 (fr)
MX (1) MX2011010151A (fr)
NZ (1) NZ595344A (fr)
PE (1) PE20120514A1 (fr)
SG (1) SG174497A1 (fr)
TW (1) TW201100104A (fr)
UA (1) UA98911C2 (fr)
UY (1) UY32514A (fr)
WO (1) WO2010108937A2 (fr)
ZA (1) ZA201107022B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
JP2013529080A (ja) 2010-05-20 2013-07-18 グラクソ グループ リミテッド 改良された抗血清アルブミン結合変異体
EP2579897A1 (fr) 2010-06-08 2013-04-17 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (fr) 2010-09-30 2017-04-05 Ablynx N.V. Matières biologiques associées à c-met
WO2012136790A1 (fr) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprenant des protéines de fusion ou des conjugués ayant une demi-vie améliorée
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IN2014CN00414A (fr) * 2011-06-23 2015-04-03 Ablynx Nv
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
WO2014118220A1 (fr) * 2013-01-31 2014-08-07 Glaxo Group Limited Procédé de production de protéine
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
SG11201606684YA (en) * 2014-02-21 2016-09-29 Medimmune Llc Anti-pcsk9~glp-1 fusions and methods for use
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
KR102698929B1 (ko) 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN112312922B (zh) 2018-06-21 2025-04-11 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
CN115485292A (zh) * 2020-03-12 2022-12-16 鄂斯尔美塔根公司 新的双特异性蛋白及其用途
KR20220008788A (ko) * 2020-07-14 2022-01-21 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
US12290463B2 (en) 2020-08-07 2025-05-06 Secured Injury Devices, Inc. Mechanism for automated injury stabilization and treatment
WO2024141054A1 (fr) * 2022-12-30 2024-07-04 苏州康宁杰瑞生物科技有限公司 Composition pharmaceutique comprenant une protéine de fusion et son utilisation
WO2025021183A1 (fr) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 Polynucléotide codant pour l'hormone adrénocorticotropique, composition associée et méthode associée

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1340288C (fr) 1988-09-02 1998-12-29 Robert Charles Ladner Production et selection de nouvelles proteines de liaison
WO1990011296A1 (fr) 1989-03-20 1990-10-04 The General Hospital Corporation Hormone insulinotrope
CA2073856C (fr) 1990-01-24 2002-12-03 Douglas I. Buckley Analogues de glp-1 pour le traitement du diabete
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
CA2262647C (fr) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methodes de regulation de la motilite gastro-intestinale
DE69841997D1 (de) 1997-07-07 2010-12-23 Medical Res Council London In-vitro-Sortierverfahren
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
WO1999025727A2 (fr) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
NZ504256A (en) 1997-11-14 2003-01-31 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for treating diabetes
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
EP1463752A4 (fr) 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1594530A4 (fr) 2003-01-22 2006-10-11 Human Genome Sciences Inc Proteines hybrides d'albumine
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
AU2005250216B2 (en) * 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20060052301A1 (en) 2004-06-03 2006-03-09 Ronen Shemesh Splice variants of peptide YY, neuropeptide Y, pancreatic peptide Y and Amylin, and uses thereof
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2259802A1 (fr) * 2008-03-31 2010-12-15 Glaxo Group Limited Fusions et conjugués médicamenteux
EP3656788A3 (fr) * 2009-02-19 2020-07-29 Glaxo Group Limited Variants de liaison anti-albumine sérique améliorés
AR075506A1 (es) * 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트

Also Published As

Publication number Publication date
PE20120514A1 (es) 2012-05-14
UY32514A (es) 2010-10-29
NZ595344A (en) 2013-09-27
BRPI1013588A2 (pt) 2016-04-19
JP2012521971A (ja) 2012-09-20
CN104127880A (zh) 2014-11-05
CL2011002387A1 (es) 2012-07-20
TW201100104A (en) 2011-01-01
SG174497A1 (en) 2011-10-28
EA021146B1 (ru) 2015-04-30
US8779103B2 (en) 2014-07-15
KR20110137819A (ko) 2011-12-23
WO2010108937A2 (fr) 2010-09-30
IL215200A0 (en) 2011-12-29
DOP2011000288A (es) 2012-01-15
CA2756853A1 (fr) 2010-09-30
US20140193407A1 (en) 2014-07-10
EA201190184A1 (ru) 2012-05-30
WO2010108937A3 (fr) 2010-11-25
US20120100141A1 (en) 2012-04-26
AR076147A1 (es) 2011-05-18
CO6361953A2 (es) 2012-01-20
EP2411054A2 (fr) 2012-02-01
AU2010227552B2 (en) 2015-02-26
CN102481373A (zh) 2012-05-30
MX2011010151A (es) 2011-12-14
AU2010227552A1 (en) 2011-11-03
ZA201107022B (en) 2013-03-27
UA98911C2 (uk) 2012-06-25

Similar Documents

Publication Publication Date Title
MA33221B1 (fr) Fusions de médicament et conjugués afférents
MX2010010776A (es) Fusiones y conjugados de farmaco.
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
BR112018075626A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
WO2022032006A9 (fr) Molécules de liaison à l'il2rb et leurs procédés d'utilisation
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA40309A1 (fr) Anticorps anti-cd73 et leurs utilisations
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
ATE312090T1 (de) 4-(piperidyl- und pyrrolidyl-alkyl-ureido)- chinoline als urotensin ii rezeptor antagonisten
WO2004019878A3 (fr) Adzymes et leurs utilisations
MA34287B1 (fr) Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
MA31403B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44